Size | Price | Stock | Qty |
---|---|---|---|
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
1g |
|
||
Other Sizes |
|
Purity: ≥98%
Rimonabant (formerly known as SR-141716; A-281; A281; SR 141716A; Acomplia; Zimulti), an anorectic antiobesity drug once used in EU but withdrawn from market due to serious psychiatric side effects, is a novel, potent and selective antagonist (inverse agonist) of cannabinoid CB1 receptor. In hCB1 transfected HEK 293 membrane, it inhibits CB1 with an IC50 of 13.6 nM and an EC50 of 17.3 nM. Anorectic anti-obesity medications include rimonabant. The main result is a decrease in appetite. (Ki=1.8nM CB1, 514nM CB2) Rimonabant has demonstrated a 285-fold selectivity for CB1. For CB1-Rs, Rimonabant has a 50-fold higher affinity than for CB2-Rs, with a Ki value of 6.18nM. Furthermore, when used as a treatment on its own,rimonabant has been shown to alter ingestive behaviors.
Targets |
hCB1 ( Ki = 0.7 nM ); rCB1 ( Ki = 2.8 nM ); MmpL3; ACAT2; ACAT1
|
||
---|---|---|---|
ln Vitro |
|
||
ln Vivo |
|
||
Enzyme Assay |
HEK 293 cells are transfected stable by human CB1 and CB2, and the cell membrane is purified. 50 mM Tris-HCl, 5 mM MgCl2, 1 mM EDTA, 0.3% BSA, pH 7.4, 0.75 nM [3H] CP55,940, and Rimonabant are added to 0.2–8 μg of the purified membrane for incubation. In the presence of 1 μM of CP55,940, the non-specific binding is defined. In Multiscreen, the reactions are incubated for 1.5 hours at 30 °C. Manifold filtration is used to stop the reactions, and ice-cold wash buffer (50 mM Tris, pH 7.4, 0.25% BSA) is used to wash the mixture four times. Topcount measures the radioactivity bound to the filters. The IC50 is computed using non-linear regression and is defined as the concentration of rimonabant needed to inhibit 50% of the binding of [3H] CP55,940.
|
||
Cell Assay |
Raw 264.7 12-well plates containing 2 × 106 cells per well are rinsed with PBS and then refed with culture media supplemented with different amounts of Rimonabant one hour before 7-ketocholesterol (7KC) is added. Equal amounts of vehicle are dispensed with in each well. Using a fluorogenic substrate (ac-DEVD-AFC) and a spectrofluorometer fitted with a microplate reader, caspase-3 and caspase 3-like activity are assessed after a 16-hour incubation.
|
||
Animal Protocol |
|
||
References |
[1]. Org Biomol Chem . 2008 Sep 21;6(18):3399-407. [2]. Biochem Biophys Res Commun . 2010 Aug 6;398(4):671-6. [3]. FEBS Lett . 1994 Aug 22;350(2-3):240-4. [4]. Int J Cancer . 2009 Sep 1;125(5):996-1003. [5]. Br J Pharmacol . 2008 Jul;154(5):1047-54. |
Molecular Formula |
C22H21CL3N4O
|
|
---|---|---|
Molecular Weight |
463.79
|
|
Exact Mass |
462.08
|
|
Elemental Analysis |
C, 56.97; H, 4.56; Cl, 22.93; N, 12.08; O, 3.45
|
|
CAS # |
168273-06-1
|
|
Related CAS # |
Rimonabant Hydrochloride; 158681-13-1; Rimonabant-d10; 929221-88-5
|
|
Appearance |
Solid powder
|
|
SMILES |
CC1=C(N(N=C1C(=O)NN2CCCCC2)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(C=C4)Cl
|
|
InChi Key |
JZCPYUJPEARBJL-UHFFFAOYSA-N
|
|
InChi Code |
InChI=1S/C22H21Cl3N4O/c1-14-20(22(30)27-28-11-3-2-4-12-28)26-29(19-10-9-17(24)13-18(19)25)21(14)15-5-7-16(23)8-6-15/h5-10,13H,2-4,11-12H2,1H3,(H,27,30)
|
|
Chemical Name |
5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidin-1-ylpyrazole-3-carboxamide
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.1561 mL | 10.7807 mL | 21.5615 mL | |
5 mM | 0.4312 mL | 2.1561 mL | 4.3123 mL | |
10 mM | 0.2156 mL | 1.0781 mL | 2.1561 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT05622994 | Not yet recruiting | Drug: Rimonabant | Hospital Nacional de Parapléjicos de Toledo |
Pfizer | November 2022 | Phase 2 |
NCT00358228 | Completed | Drug: Rimonabant | Smoking Cessation | Sanofi | September 2002 | Phase 3 |
NCT00464165 | Completed | Drug: rimonabant | Smoking Cessation | Sanofi | November 2002 | Phase 3 |
NCT00464256 | Completed | Drug: rimonabant | Smoking Cessation | Sanofi | November 2004 | Phase 3 |
NCT05398913 | Recruiting | Drug: Rimonabant | Spinal Cord Injuries | Hospital Nacional de Parapléjicos de Toledo |
May 12, 2021 | Phase 1 Phase 2 |
Rimonabant selectively inhibits cholesteryl ester synthesis in macrophages. Biochem Biophys Res Commun . 2010 Aug 6;398(4):671-6. td> |
Rimonabant inhibits oxysterol-stimulated and AcLDL-stimulated ACAT activity in macrophages. Biochem Biophys Res Commun . 2010 Aug 6;398(4):671-6. td> |
Rimonabant decreases cell recovery and induces cell death in colon cancer cells. DLD-1, Caco-2 and SW620 cells were treated with rimonabant (0–20 μM) for 24 and 48 hr. Int J Cancer . 2009 Sep 1;125(5):996-1003. td> |
Rimonabant affects cell cycle phase distribution in colon cancer cells. DLD-1, Caco-2 and SW620 were exposed to rimonabant for 24 hr (0–10 μM). Int J Cancer . 2009 Sep 1;125(5):996-1003. td> |
Body weight in 3-month-old obese Zucker rats after 2 weeks of treatment with or without rimonabant (Rimo, a) compared with lean Zucker rats of the same ages, and weight gain in 6-month-old lean and obese Zucker rats after 10 weeks of treatment with or without rimonabant (Rimo, b). Br J Pharmacol . 2008 Jul;154(5):1047-54 td> |
Subthreshold doses of rimonabant (0.3 mg/kg) and donepezil (0.1 mg/kg) given in combination decreased the number of errors committed in the test phase. Neuropsychopharmacology . 2007 Aug;32(8):1805-12. td> |
A Unique Binding Mode for Rimonabant. Cell . 2019 Jan 24;176(3):636-648.e13. td> |